SCHEMBL6891152

SCHEMBL6891152

CSc1nc(C(C)=O)n2ccsc12

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
PTGS1 P23219 2/20 0.35
PTGS2 P35354 2/20 0.35
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPK1 P28482 1/20 0.33
TSHR P16473 2/20 0.33
CYP1A2 P05177 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALOX12 P18054 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.32
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771198 0.75 ALOX12 (0.36) PTGS1PTGS2MAPK1CYP1A2TDP1
SCHEMBL6891624 0.73 PTGS1 (0.38) PTGS1PTGS2ALOX12
SCHEMBL6887261 0.70 MEN1 (0.36) KDM4EPTGS1PTGS2HPGDALDH1A1
SCHEMBL9516840 0.67 MAPK1 (0.46) KDM4EPTGS1PTGS2HPGDSMN1; SMN2
SCHEMBL6890415 0.66 KDM4E (0.41) KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL6771897 0.62 PTGS1 (0.31) PTGS1PTGS2
SCHEMBL9517362 0.61 MAPK1 (0.71) KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10
SCHEMBL6626573 0.60 PTGS1 (0.35) PTGS1PTGS2ALOX12
SCHEMBL2338659 0.60 MAPK1 (0.65) MAPK1CYP1A2TDP1ALOX12
SCHEMBL3762990 0.59 ALDH1A1 (0.56) KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 KDM4E 1406/4885PTGS1 1759/4885PTGS2 3583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.